KIORA PHARMACEUTICALS, INC. Cash and Cash Equivalents, Fair Value Disclosure
KIORA PHARMACEUTICALS, INC. (KPRX) had Cash and Cash Equivalents, Fair Value Disclosure of $2.94 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Fair Value Disclosures › Financial Instruments, Financial Assets, Balance Sheet Groupings
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-07
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $2.94M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $8.30M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $6.80M.
- 2024-12-31: Cash and Cash Equivalents, Fair Value Disclosure $1.25M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $2.94M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $8.30M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $6.80M 10-Q · filed 2026-08-07 |
| 2024-12-31 | $1.25M 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |